SCHEMBL5611280

SCHEMBL5611280

CCCCN(CC)c1nc(C)nc2c1c(S(C)(=O)=O)nn2-c1c(Cl)cc(Cl)cc1Cl

nearest known ligand 0.56

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CRHR1 P34998 20/20 0.56
TDP1 Q9NUW8 1/20 0.48
FPR3 P25089 2/20 0.47
TSPO P30536 2/20 0.47
TMEM97 Q5BJF2 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7968457 0.93 CRHR1 (0.48) CRHR1TDP1FPR3TSPOTMEM97
SCHEMBL9018497 0.92 CRHR1 (0.45) CRHR1TDP1FPR3TSPOTMEM97
SCHEMBL7967906 0.92 CRHR1 (0.43) CRHR1
SCHEMBL5600433 0.83 CRHR1 (0.57) CRHR1TDP1FPR3TSPOTMEM97
SCHEMBL7965770 0.81 CDK4 (0.40) CRHR1TDP1
SCHEMBL7961772 0.81 TDP1 (0.40) CRHR1TDP1
SCHEMBL5600331 0.79 CDK4 (0.53) CRHR1TDP1
SCHEMBL7427284 0.76 GLP1R (0.41) CRHR1
SCHEMBL5599902 0.75 CDK4 (0.52) CRHR1
SCHEMBL5599534 0.75 CDK4 (0.53) CRHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2007522200-A 2007-08-09 JP claimed
EP-1718311-A1 THERAPEUTIC COMBINATIONS OF ATYPICAL ANTIPSYCHOTICS WITH CORTICOTROPIN RELEASING FACTOR ANTAGONISTS Pfizer Products Incorporated (US) 2006-11-08 EP claimed
US-20050209250-A1 Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists PFIZER INC 2005-09-22 US claimed
WO-2005079807-A1 THERAPEUTIC COMBINATIONS OF ATYPICAL ANTIPSYCHOTICS WITH CORTICOTROPIN RELEASING FACTOR ANTAGONISTS PFIZER PRODUCTS INC. (US) 2005-09-01 WO claimed
US-20040082597-A1 Use of CRF antagonists and related compositions PFIZER INC 2004-04-29 US claimed
US-20030199527-A1 Use of corticotropin releasing factor antagonists and related compositions HAMANAKA ERNEST S (US) 2003-10-23 US claimed
US-20020156089-A1 Use of CRF antagonists and related compositions PFIZER INC. 2002-10-24 US claimed
US-6432989-B1 TREATING SLEEP DISORDERS PFIZER INC 2002-08-13 US claimed
US-6387894-B1 MIXTURE OF CORTICOTROPIN RELEASING FACTOR ANTAGINIST AND RENIN-ANGIOTENSIN SYSTEM INHIBITOR; THERAPY FOR CONGESTIVE HEART FAILURE, HYPOTENSIVE AGENTS PFIZER INC. 2002-05-14 US claimed
US-6384039-B1 ADMINISTERING CORTICOTROPIN RELEASING FACTOR ANTAGONIST PFIZER INC. 2002-05-07 US claimed
EP-1149583-A2 Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues Pfizer Products Inc. (US) 2001-10-31 EP claimed
EP-1097709-A2 Use of corticotropin releasing factor antagonists for treating syndrome X Pfizer Products Inc. (US) 2001-05-09 EP claimed
US-20010000340-A1 New uses for corticotropin releasing factor antagonists CHEN YUHPYNG L (US) 2001-04-19 US claimed
EP-1082960-A2 Use of CRF antagonists and related compositions for treating depression and modifying the circadian rhytm Pfizer Products Inc. (US) 2001-03-14 EP claimed
EP-1059100-A2 Combinations of CRF antagonists and renin-angiotensin system inhibitors Pfizer Products Inc. (US) 2000-12-13 EP claimed
EP-1040831-A2 Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death Pfizer Products Inc. (US) 2000-10-04 EP claimed
US-6051578-A Pyrazolopyrimidines for treatment of CNS disorders PFIZER INC. (US) 2000-04-18 US claimed
EP-0773023-A1 New uses for corticotropin releasing factor (CRF) antagonists PFIZER INC. (US) 1997-05-14 EP claimed
EP-0729758-A2 Pyrazolopyrimidines and pyrrolopyrimidines for treatment of neuronal and other disorders PFIZER INC. (US) 1996-09-04 EP claimed
CN-1094048-A Pyrazolopyrimidines PFIZER (US) 1994-10-26 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050209250-A1 Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists CRH, MC2R, CRHR2 CRHR1 5/4885TDP1 3496/4885FPR3 752/4885
US-20020156089-A1 Use of CRF antagonists and related compositions CRH, CRHR1, CRHR2 CRHR1 2/4885TDP1 4639/4885FPR3 410/4885
US-20010000340-A1 New uses for corticotropin releasing factor antagonists CRH, CRHR1, CRHR2 CRHR1 2/4885TDP1 3514/4885FPR3 44/4885
US-20030199527-A1 Use of corticotropin releasing factor antagonists and related compositions CRH, CRHR1, CRHR2 CRHR1 2/4885TDP1 3537/4885FPR3 70/4885
US-20040082597-A1 Use of CRF antagonists and related compositions CRH, CRHR1, CRHR2 CRHR1 2/4885TDP1 4639/4885FPR3 410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.